FDA Commissioner Marty Makary announced the news to FDA staff in an email late Friday, saying Vinay Prasad would depart at ...

Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate. | Disc Medicine is laying off a fifth of its workforce as the ...

This clinical-stage biopharmaceutical company recently had one of its treatments rejected for FDA approval. Now the company ...

USA: A phase 2a pilot trial evaluating dual costimulatory blockade with dazodalibep plus belatacept suggests this approach may improve immunosuppression adherence and offer a ...

Acadia Pharmaceuticals isn’t taking its recent rejection from the European Medicines Agency lying down, vowing to seek a ...

Scientific, political pressures colliding at FDA, delaying rare disease treatment for patients who have few or no options, experts said at CNBC Cures Summit.

A new technology has been developed to suppress immune rejection, the biggest challenge in organ transplantation, without ...

Center for Biologics Evaluation and Research Director Vinay Prasad will exit the FDA for the second time after a controversial run that saw the oncologist butt heads with colleagues and ruffle ...

Without naming a specific product, Commissioner Marty Makary referred to an investigational therapy, delivered surgically ...

A new technology has been developed to suppress immune rejection, the biggest challenge in organ transplantation, without causing systemic side effects. A research team from Pohang University of ...

It makes rejection, teasing or criticism feel unbearable, often prompting a strong physical reaction. Sufferers describe life with a condition that is only just starting to be understood ...

Thermo Fisher Scientific is launching a new test it says can help doctors avoid the “trial-and-error” approach typically used to dose patients with a common antirejection drug after organ transplant ...